24 Diagnostic Applications of Phycobiliproteins
595
Table 24.3 (continued)
Disease/diagnostic parameters
Patents-source/country and number
Leukemia
KR100759289 (E)
Leukemia fusion gene
CN203021568 (E), WO2011120398 (E),
WO2011157222 (E), CN101838682 (E), CN
101955995, CN 101955991
Stem cell cancer
IN 636/DELNP/2015, IN 7062/CHENP/2012
B cell leukemia
CN103018463 (E)
Polycythemia vera
(slow growing blood cancer)
BG1777 (E)
Acute leukemia and lymphoblastic
lymphoma
IN 8730/DELNP/2007
Pediatric acute lymphoblastic leukemia
IN 2963/DEL/2013
Monitoring of multiple myeloma
RU2639382 (E)
(D) Other cancer assessments
Recurrence of blood cancer after surgery
RU2017105638 (E)
Prognosis of survival time of solid tumor
patients and treatment responsiveness
IN 201817045553
IF-α producing T-lymphocytes in chronic
lymphatic leukemia
RU2526797 (E)
Phosphorylation status of retinoblastoma
(eye cancer)
US 6821740
Abbreviations: CN—CNIPA database, China; (E)—Espacenet database, European Patent Office;
IN—InPASS database, India; JP—J-Plat Pat database, Japan; KR—KIPRIS database, Korea; US—
USPTO database, United States of America
Patent numbers represent application numbers except numbers with prefix “CN” and suffix “(E)”
that denote publication numbers. Except Espacenet, numbers alone (without prefix alphabets) have
to be entered in the suitable search field of the corresponding country’s database. Such prefix
alphabets are meant for identifying the database. In Espacenet alone (tagged with “(E)” as suffix
of numbers), given alphabetic prefix along with the publication numbers have to be fed to access
patent details
24.2.4 Diagnosis of Human Immune Disorders
Parallel to the previously reported cases of diagnostics, detection of human immune
disorders using PBPs tags was also patented extensively. In this case, diagnosis
of general immune disorders, antibody-mediated immune disorders, and certain
assessments of immunity were patented (Table 24.4).
595
Table 24.3 (continued)
Disease/diagnostic parameters
Patents-source/country and number
Leukemia
KR100759289 (E)
Leukemia fusion gene
CN203021568 (E), WO2011120398 (E),
WO2011157222 (E), CN101838682 (E), CN
101955995, CN 101955991
Stem cell cancer
IN 636/DELNP/2015, IN 7062/CHENP/2012
B cell leukemia
CN103018463 (E)
Polycythemia vera
(slow growing blood cancer)
BG1777 (E)
Acute leukemia and lymphoblastic
lymphoma
IN 8730/DELNP/2007
Pediatric acute lymphoblastic leukemia
IN 2963/DEL/2013
Monitoring of multiple myeloma
RU2639382 (E)
(D) Other cancer assessments
Recurrence of blood cancer after surgery
RU2017105638 (E)
Prognosis of survival time of solid tumor
patients and treatment responsiveness
IN 201817045553
IF-α producing T-lymphocytes in chronic
lymphatic leukemia
RU2526797 (E)
Phosphorylation status of retinoblastoma
(eye cancer)
US 6821740
Abbreviations: CN—CNIPA database, China; (E)—Espacenet database, European Patent Office;
IN—InPASS database, India; JP—J-Plat Pat database, Japan; KR—KIPRIS database, Korea; US—
USPTO database, United States of America
Patent numbers represent application numbers except numbers with prefix “CN” and suffix “(E)”
that denote publication numbers. Except Espacenet, numbers alone (without prefix alphabets) have
to be entered in the suitable search field of the corresponding country’s database. Such prefix
alphabets are meant for identifying the database. In Espacenet alone (tagged with “(E)” as suffix
of numbers), given alphabetic prefix along with the publication numbers have to be fed to access
patent details
24.2.4 Diagnosis of Human Immune Disorders
Parallel to the previously reported cases of diagnostics, detection of human immune
disorders using PBPs tags was also patented extensively. In this case, diagnosis
of general immune disorders, antibody-mediated immune disorders, and certain
assessments of immunity were patented (Table 24.4).